Announcements Trials
Browse Landscape

Phase

Phase 2 106Phase 1 55Phase 1/2 42Phase 3 18Phase EARLY_PHASE1 5Phase 2/3 4Phase NA 3Phase 4 3

Status

Completed 2Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 5CNS 1

Conditions

Melanoma 5Neoplasm Metastasis 2Carcinoma, Renal Cell 2Uveal Melanoma 1Skin Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Motor Activity 1Lymphoid Interstitial Pneumonia 1Laryngeal Diseases 1Carcinoma, Merkel Cell 1Brain Neoplasms 1

Interventions

Nivolumab 9pembrolizumab 6Ipilimumab 5Magnetic Resonance Spectroscopy 3resiquimod 2encorafenib 2binimetinib 2aldesleukin 2Oncolytic Virotherapy 2MART-1 Antigen 2Interleukin-2 2Cyclophosphamide 2urelumab 1tremelimumab 1tetraethylpyrazine 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1relatlimab 1montanide ISA 51 1glucopyranosyl lipid-A 1fludarabine phosphate 1fludarabine 1durvalumab 1clevudine 1cemiplimab 1avelumab 1Specimen Handling 1Sentinel Lymph Node Biopsy 1S 28463 1Radiotherapy 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Melanoma × Ipilimumab × Clear all
NCT05498792 2026-05-22

Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

Fox Chase Cancer Center

Phase EARLY_PHASE1 Recruiting
12 enrolled
Dermatologic

Melanoma

NCT05704933 2026-04-06

Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Completed
1 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Active not recruiting
22 enrolled
Dermatologic

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

NCT03526185 2022-07-25

A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes

Yale University

Phase EARLY_PHASE1 Terminated
6 enrolled
Dermatologic

Melanoma

NCT00972933 2017-12-07

Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma

University of Pittsburgh

Phase EARLY_PHASE1 Completed
59 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡